Product Description
Mechanisms of Action: GM-CSF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous,Oral
FDA Designation: Orphan Drug - Arteritis|Giant Cell Arteritis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: COVID-19|Inflammation|Pneumonia|Respiratory Insufficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Mavrilimumab in COVID-19 pneumonia with hyperinflammation | P2 |
Active, not recruiting |
Inflammation|Respiratory Insufficiency|COVID-19|Pneumonia |
2020-09-07 |